Emerging roles of PHLPP phosphatases in metabolism |
Cha, Jong-Ho
(Department of Biomedical Sciences, College of Medicine, Inha University)
Jeong, Yelin (Department of Biomedical Sciences, College of Medicine, Inha University) Oh, Ah-Reum (Department of Biomedical Sciences, College of Medicine, Inha University) Lee, Sang Bae (Division of Life Sciences, Jeonbuk National University: Sarcopenia Total Solution Center) Hong, Soon-Sun (Department of Biomedical Sciences, College of Medicine, Inha University) Kim, KyeongJin (Department of Biomedical Sciences, College of Medicine, Inha University) |
1 | Savage DB and Semple RK (2010) Recent insights into fatty liver, metabolic dyslipidaemia and their links to insulin resistance. Curr Opin Lipidol 21, 329-336 DOI |
2 | Cozzone D, Frojdo S, Disse E et al (2008) Isoform-specific defects of insulin stimulation of Akt/protein kinase B (PKB) in skeletal muscle cells from type 2 diabetic patients. Diabetologia 51, 512-521 DOI |
3 | Johnson AM and Olefsky JM (2013) The origins and drivers of insulin resistance. Cell 152, 673-684 DOI |
4 | Behera S, Kapadia B, Kain V et al (2018) ERK1/2 activated PHLPP1 induces skeletal muscle ER stress through the inhibition of a novel substrate AMPK. Biochim Biophys Acta Mol Basis Dis 1864, 1702-1716 DOI |
5 | Newton AC and Trotman LC (2014) Turning off AKT: PHLPP as a drug target. Annu Rev Pharmacol Toxicol 54, 537-558 DOI |
6 | Jacinto E, Loewith R, Schmidt A et al (2004) Mammalian TOR complex 2 controls the actin cytoskeleton and is rapamycin insensitive. Nat Cell Biol 6, 1122-1128 DOI |
7 | Laplante M and Sabatini DM (2012) mTOR signaling in growth control and disease. Cell 149, 274-293 DOI |
8 | Kim K and Pajvani UB (2016) "Free" Raptor - a novel regulator of metabolism. Cell Cycle 15, 1174-1175 DOI |
9 | Kim K, Ryu D, Dongiovanni P et al (2017) Degradation of PHLPP2 by KCTD17, via a glucagon-dependent pathway, promotes hepatic steatosis. Gastroenterology 153, 1568-1580 e1510 DOI |
10 | Christensen AA and Gannon M (2019) The beta cell in type 2 diabetes. Curr Diab Rep 19, 81 DOI |
11 | Yu Y, Dai M, Lu A, Yu E and Merlino G (2018) PHLPP1 mediates melanoma metastasis suppression through repressing AKT2 activation. Oncogene 37, 2225-2236 DOI |
12 | Kim K, Kang JK, Jung YH et al (2021) Adipocyte PHLPP2 inhibition prevents obesity-induced fatty liver. Nat Commun 12, 1822 DOI |
13 | Cai J, Fang L, Huang Y et al (2013) miR-205 targets PTEN and PHLPP2 to augment AKT signaling and drive malignant phenotypes in non-small cell lung cancer. Cancer Res 73, 5402-5415 DOI |
14 | Gao G, Kun T, Sheng Y et al (2013) SGT1 regulates Akt signaling by promoting beta-TrCP-dependent PHLPP1 degradation in gastric cancer cells. Mol Biol Rep 40, 2947-2953 DOI |
15 | O'Hayre M, Niederst M, Fecteau JF et al (2012) Mechanisms and consequences of the loss of PHLPP1 phosphatase in chronic lymphocytic leukemia (CLL). Leukemia 26, 1689-1692 DOI |
16 | Loomba R and Sanyal AJ (2013) The global NAFLD epidemic. Nat Rev Gastroenterol Hepatol 10, 686-690 DOI |
17 | Hribal ML, Perego L, Lovari S et al (2003) Chronic hyperglycemia impairs insulin secretion by affecting insulin receptor expression, splicing, and signaling in RIN beta cell line and human islets of Langerhans. FASEB J 17, 1340-1342 DOI |
18 | Elghazi L, Balcazar N and Bernal-Mizrachi E (2006) Emerging role of protein kinase B/Akt signaling in pancreatic betacell mass and function. Int J Biochem Cell Biol 38, 157-163 DOI |
19 | Hribal ML, Mancuso E, Arcidiacono GP et al (2020) The phosphatase PHLPP2 plays a key role in the regulation of pancreatic beta-cell survival. Int J Endocrinol 2020, 1027386 |
20 | Araujo AR, Rosso N, Bedogni G, Tiribelli C and Bellentani S (2018) Global epidemiology of non-alcoholic fatty liver disease/non-alcoholic steatohepatitis: What we need in the future. Liver Int 38 Suppl 1, 47-51 DOI |
21 | Kim K and Kim KH (2020) Targeting of secretory proteins as a therapeutic strategy for treatment of nonalcoholic steatohepatitis (NASH). Int J Mol Sci 21, 2296 DOI |
22 | Brazil DP and Hemmings BA (2001) Ten years of protein kinase B signalling: a hard Akt to follow. Trends Biochem Sci 26, 657-664 DOI |
23 | Hsu AH, Lum MA, Shim KS et al (2018) Crosstalk between PKCalpha and PI3K/AKT signaling is tumor suppressive in the endometrium. Cell Rep 24, 655-669 DOI |
24 | Gao T, Brognard J and Newton AC (2008) The phosphatase PHLPP controls the cellular levels of protein kinase C. J Biol Chem 283, 6300-6311 DOI |
25 | Liu J, Stevens PD, Li X, Schmidt MD and Gao T (2011) PHLPP-mediated dephosphorylation of S6K1 inhibits protein translation and cell growth. Mol Cell Biol 31, 4917-4927 DOI |
26 | Baffi TR, Van AN, Zhao W, Mills GB and Newton AC (2019) Protein kinase C quality control by phosphatase phlpp1 unveils loss-of-function mechanism in cancer. Mol Cell 74, 378-392 e375 DOI |
27 | Qiao M, Wang Y, Xu X et al (2010) Mst1 is an interacting protein that mediates PHLPPs' induced apoptosis. Mol Cell 38, 512-523 DOI |
28 | Isotani S, Hara K, Tokunaga C, Inoue H, Avruch J and Yonezawa K (1999) Immunopurified mammalian target of rapamycin phosphorylates and activates p70 S6 kinase alpha in vitro. J Biol Chem 274, 34493-34498 DOI |
29 | Li X, Stevens PD, Liu J et al (2014) PHLPP is a negative regulator of RAF1, which reduces colorectal cancer cell motility and prevents tumor progression in mice. Gastroenterology 146, 1301-1312 e1301-1310 DOI |
30 | Ellwood-Yen K, Graeber TG, Wongvipat J et al (2003) Myc-driven murine prostate cancer shares molecular features with human prostate tumors. Cancer Cell 4, 223-238 DOI |
31 | Baffi TR, Cohen-Katsenelson K and Newton AC (2021) PHLPPing the script: emerging roles of PHLPP phosphatases in cell signaling. Annu Rev Pharmacol Toxicol 61, 723-743 DOI |
32 | Shimizu K, Okada M, Takano A and Nagai K (1999) SCOP, a novel gene product expressed in a circadian manner in rat suprachiasmatic nucleus. FEBS Lett 458, 363-369 DOI |
33 | Brognard J, Sierecki E, Gao T and Newton AC (2007) PHLPP and a second isoform, PHLPP2, differentially attenuate the amplitude of Akt signaling by regulating distinct Akt isoforms. Mol Cell 25, 917-931 DOI |
34 | Brognard J and Newton AC (2008) PHLiPPing the switch on Akt and protein kinase C signaling. Trends Endocrinol Metab 19, 223-230 DOI |
35 | Molina JR, Agarwal NK, Morales FC et al (2012) PTEN, NHERF1 and PHLPP form a tumor suppressor network that is disabled in glioblastoma. Oncogene 31, 1264-1274 DOI |
36 | Reyes G, Niederst M, Cohen-Katsenelson K et al (2014) Pleckstrin homology domain leucine-rich repeat protein phosphatases set the amplitude of receptor tyrosine kinase output. Proc Natl Acad Sci U S A 111, E3957-3965 |
37 | Kim K, Qiang L, Hayden MS, Sparling DP, Purcell NH and Pajvani UB (2016) mTORC1-independent raptor prevents hepatic steatosis by stabilizing PHLPP2. Nat Commun 7, 10255 DOI |
38 | Chang DW, Claassen GF, Hann SR and Cole MD (2000) The c-Myc transactivation domain is a direct modulator of apoptotic versus proliferative signals. Mol Cell Biol 20, 4309-4319 DOI |
39 | Schwartz JP and Jungas RL (1971) Studies on the hormone-sensitive lipase of adipose tissue. J Lipid Res 12, 553-562 DOI |
40 | Sarbassov DD, Ali SM, Kim DH et al (2004) Rictor, a novel binding partner of mTOR, defines a rapamycin-in-sensitive and raptor-independent pathway that regulates the cytoskeleton. Curr Biol 14, 1296-1302 DOI |
41 | Weyer C, Bogardus C, Mott DM and Pratley RE (1999) The natural history of insulin secretory dysfunction and insulin resistance in the pathogenesis of type 2 diabetes mellitus. J Clin Invest 104, 787-794 DOI |
42 | Ye R, Onodera T and Scherer PE (2019) Lipotoxicity and beta cell maintenance in obesity and type 2 diabetes. J Endocr Soc 3, 617-631 DOI |
43 | Sesti G, Federici M, Lauro D, Sbraccia P and Lauro R (2001) Molecular mechanism of insulin resistance in type 2 diabetes mellitus: role of the insulin receptor variant forms. Diabetes Metab Res Rev 17, 363-373 DOI |
44 | Goodyear LJ and Kahn BB (1998) Exercise, glucose transport, and insulin sensitivity. Annu Rev Med 49, 235-261 DOI |
45 | Gao T, Furnari F and Newton AC (2005) PHLPP: a phosphatase that directly dephosphorylates Akt, promotes apoptosis, and suppresses tumor growth. Mol Cell 18, 13-24 DOI |
46 | Nigro C, Mirra P, Prevenzano I et al (2018) miR-214-dependent increase of PHLPP2 levels mediates the impairment of insulin-stimulated Akt activation in mouse aortic endothelial cells exposed to methylglyoxal. Int J Mol Sci 19, 522 DOI |
47 | Sun X, Lin J, Zhang Y et al (2016) MicroRNA-181b improves glucose homeostasis and insulin sensitivity by regulating endothelial function in white adipose tissue. Circ Res 118, 810-821 DOI |
48 | Mathur A, Pandey VK and Kakkar P (2017) PHLPP: a putative cellular target during insulin resistance and type 2 diabetes. J Endocrinol 233, R185-R198 DOI |
49 | Xiong X, Wen YA, Mitov MI, M CO, Miyamoto S and Gao T (2017) PHLPP regulates hexokinase 2-dependent glucose metabolism in colon cancer cells. Cell Death Discov 3, 16103 DOI |
50 | Ohwada W, Tanno M, Yano T et al (2020) Distinct intra-mitochondrial localizations of pro-survival kinases and regulation of their functions by DUSP5 and PHLPP-1. Biochim Biophys Acta Mol Basis Dis 1866, 165851 DOI |
51 | Aviv Y and Kirshenbaum LA (2010) Novel phosphatase PHLPP-1 regulates mitochondrial Akt activity and cardiac cell survival. Circ Res 107, 448-450 DOI |
52 | Li X, Stevens PD, Yang H et al (2013) The deubiquitination enzyme USP46 functions as a tumor suppressor by controlling PHLPP-dependent attenuation of Akt signaling in colon cancer. Oncogene 32, 471-478 DOI |
53 | Tovell H and Newton AC (2021) PHLPPing the balance: restoration of protein kinase C in cancer. Biochem J 478, 341-355 DOI |
54 | Postic C and Girard J (2008) Contribution of de novo fatty acid synthesis to hepatic steatosis and insulin resistance: lessons from genetically engineered mice. J Clin Invest 118, 829-838 DOI |
55 | Ma XM and Blenis J (2009) Molecular mechanisms of mTOR-mediated translational control. Nat Rev Mol Cell Biol 10, 307-318 DOI |
56 | Nowak DG, Katsenelson KC, Watrud KE et al (2019) The PHLPP2 phosphatase is a druggable driver of prostate cancer progression. J Cell Biol 218, 1943-1957 DOI |
57 | McKeown MR and Bradner JE (2014) Therapeutic strategies to inhibit MYC. Cold Spring Harb Perspect Med 4, a014266 DOI |
58 | Andreozzi F, Procopio C, Greco A et al (2011) Increased levels of the Akt-specific phosphatase PH domain leucine-rich repeat protein phosphatase (PHLPP)-1 in obese participants are associated with insulin resistance. Diabetologia 54, 1879-1887 DOI |
59 | Wu J, Dong T, Chen T et al (2020) Hepatic exosome-derived miR-130a-3p attenuates glucose intolerance via suppressing PHLPP2 gene in adipocyte. Metabolism 103, 154006 DOI |
60 | Mendoza MC and Blenis J (2007) PHLPPing it off: phosphatases get in the Akt. Mol Cell 25, 798-800 DOI |
61 | Zhang LL, Cao FF, Wang Y et al (2015) The protein kinase C (PKC) inhibitors combined with chemotherapy in the treatment of advanced non-small cell lung cancer: meta-analysis of randomized controlled trials. Clin Transl Oncol 17, 371-377 DOI |
62 | Burnett PE, Barrow RK, Cohen NA, Snyder SH and Sabatini DM (1998) RAFT1 phosphorylation of the translational regulators p70 S6 kinase and 4E-BP1. Proc Natl Acad Sci U S A 95, 1432-1437 DOI |
63 | Wellbrock C, Karasarides M and Marais R (2004) The RAF proteins take centre stage. Nat Rev Mol Cell Biol 5, 875-885 DOI |
64 | Hemann MT, Bric A, Teruya-Feldstein J et al (2005) Evasion of the p53 tumour surveillance network by tumour-derived MYC mutants. Nature 436, 807-811 DOI |
65 | Chang RM, Yang H, Fang F, Xu JF and Yang LY (2014) MicroRNA-331-3p promotes proliferation and metastasis of hepatocellular carcinoma by targeting PH domain and leucine-rich repeat protein phosphatase. Hepatology 60, 1251-1263 DOI |
66 | Smith AJ, Wen YA, Stevens PD, Liu J, Wang C and Gao T (2016) PHLPP negatively regulates cell motility through inhibition of Akt activity and integrin expression in pancreatic cancer cells. Oncotarget 7, 7801-7815 DOI |
67 | Younossi Z, Anstee QM, Marietti M et al (2018) Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention. Nat Rev Gastroenterol Hepatol 15, 11-20 DOI |